We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCAT icon
526
Health Catalyst
HCAT
$160M
– –
-13,508
Closed -$86.3K
HCC icon
527
Warrior Met Coal
HCC
$4.17B
– –
-14,264
Closed -$895K
HCI icon
528
HCI Group
HCI
$2.34B
– –
-9,779
Closed -$901K
HD icon
529
Home Depot
HD
$337B
– –
-1,923
Closed -$662K
HOLX
530
DELISTED
Hologic
HOLX
– –
-13,734
Closed -$1.02M
HOOD icon
531
Robinhood
HOOD
$80.7B
– –
-10,823
Closed -$246K
HR icon
532
Healthcare Realty
HR
$7.56B
– –
-28,566
Closed -$471K
HSIC icon
533
Henry Schein
HSIC
$9.78B
– –
-13,479
Closed -$864K
HSTM icon
534
HealthStream
HSTM
$863M
– –
-22,437
Closed -$626K
HSY icon
535
Hershey
HSY
$37.3B
– –
-5,032
Closed -$925K
HUMA icon
536
Humacyte
HUMA
$168M
– –
-322,851
Closed -$1.55M
HXL icon
537
Hexcel
HXL
$7.97B
– –
-23,879
Closed -$1.49M
IART icon
538
Integra LifeSciences
IART
$1.28B
– –
-1,467,632
Closed -$42.8M
ILPT
539
Industrial Logistics Properties Trust
ILPT
$582M
– –
-147,321
Closed -$542K
IMMR icon
540
Immersion
IMMR
$243M
– –
-56,830
Closed -$535K
INOD icon
541
Innodata
INOD
$1.81B
– –
-111,814
Closed -$1.66M
INSP icon
542
Inspire Medical Systems
INSP
$1.47B
– –
-2,813
Closed -$376K
INTU icon
543
Intuit
INTU
$91.1B
– –
-2,197
Closed -$1.44M
INZY
544
DELISTED
Inozyme Pharma
INZY
– –
-11,591
Closed -$51.7K
IT icon
545
Gartner
IT
$11.1B
– –
-754
Closed -$339K
ITOS
546
DELISTED
iTeos Therapeutics
ITOS
– –
-723,000
Closed -$10.7M
ITW icon
547
Illinois Tool Works
ITW
$84.1B
– –
-4,341
Closed -$1.03M
IVT icon
548
InvenTrust Properties
IVT
$2.79B
– –
-17,390
Closed -$431K
JAMF
549
DELISTED
Jamf
JAMF
– –
-34,231
Closed -$565K
JBI icon
550
Janus International
JBI
$702M
– –
-26,179
Closed -$331K
20 21
22
23 24

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.